Danish pharmaceutical leader Novo Nordisk slashed its 2025 sales growth forecast to 8%-14% from the prior 13%-21% range due to increasing competition from compounded semaglutide generics affecting blockbuster obesity drug Wegovy and diabetes medication Ozempic. The company also announced leadership transition, naming veteran Maziar Mike Doustdar as new CEO, effective August 7, following Lars Fruergaard Jørgensen’s planned departure. Despite innovation in the fastest-growing pharma market, Novo faces hurdles including supply issues, failed partnerships, and shifting vaccination recommendations impacting its pipeline and stock performance.